Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, Cui Q, Mu Q, Chen G, Han L, Guo T, Cui J, Jiang X, Zheng X, Yu S, Li X, Zhang X, Chen M, Li X, Gao M, Wang K, Zu C, Zhang H, He X, Wang Y, Wang D, Ren J, Huang H.
Hu Y, et al. Among authors: gao m.
Cell Res. 2022 Nov;32(11):995-1007. doi: 10.1038/s41422-022-00721-y. Epub 2022 Sep 23.
Cell Res. 2022.
PMID: 36151216
Free PMC article.
Clinical Trial.